Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?

Autor: Şam Özdemir M; Department of Radiology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey. mervesam@msn.com., Kaya N; Department of Radiology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Savun M; Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Keskin ET; Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Yüzkan S; Department of Radiology, Koc University, Istanbul, Turkey., Arslan FZ; Department of Radiology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Budak B; Department of Radiology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Omak Ö; Department of Nucleer Medicine, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Yardımcı AH; Department of Radiology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey., Özdemir H; Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: World journal of surgical oncology [World J Surg Oncol] 2024 Dec 20; Vol. 22 (1), pp. 339. Date of Electronic Publication: 2024 Dec 20.
DOI: 10.1186/s12957-024-03578-0
Abstrakt: Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods and Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized. This work investigates the use of mpMRI to describe incidental 18 F-FDG uptake in the prostate.mpMRI included T2-weighted (T2W), dynamic contrast enhancement (DCE), and apparent diffusion coefficient (ADC) sequences. Patients were classified according to PI-RADS (Prostate Imaging Reporting and Data System) version 2.1 by an experienced uroradiologist, and 18 F-FDG-PET was evaluated to determine whether the area of involvement on CT had a counterpart in mpMRI. A biopsy was performed on 30 of the 92 patients. These patients' maximum standardized uptake values (SUVmax) 6 < and ≥ 6, PS(PSA) density 0.15 < and ≥ 0.15, PSA level, uptake pattern (focal involvement/diffuse involvement), and PI-RADS scores were compared. P < .05 was considered statistically significant. Logistic regression was used to analyze PI-RADS score groups age, PSA, PSA density and SUVmax.
Results: In the study, 92 patients with incidental 18 F-FDG-PET/CT prostate uptake were examined. Median age was 66, PSA median was 3.6 ng/ml (range: 0-3198 ng/ml). Notably, in 70.6% of cases, PET/CT uptake didn't correlate with mp-MRI findings. Among PI-RADS 3-4-5 patients (29.3%), there was a correlation. Biopsies in 30 patients revealed 43.3% benign, 56.7% malignant. Significant differences between benign and malignant cases were observed in PSA density, PI-RADS scores, and PSA levels (p < .05), while SUVmax and uptake pattern were not significant. In multivariate logistic regression analysis, PI-RADS score groups were found to be independent risk factors for predicting malignancy.
Conclusions: Our study showed that incidental 18 F-FDG-PET/CT prostate uptake was detected and that high PSA density values, PI-RADS scores, and PSA values, such as in routine patients, and not PET-CT findings such as SUVmax and uptake pattern, were more predictive of malignancy.
Competing Interests: Declarations. Ethics approval and consent to participate: Our study, which included human participants, was reviewed and approved by the ethics committee of Basaksehir Cam and Sakura Hospital. The ethics committee approval is attached. Our study was conducted retrospectively by scanning patients through the PACS system. Our patients sign informed consent documents stating that their information can be used when undergoing MRI scans, but a new informed consent form has not been signed with the information of the ethics committee. The ethics committee decision was uploaded to the system as an additional file. Ethical approval of the present single-center study was granted by the local ethics committee (E-96317027-514.10-232789128; decision date: 29/12/2023) and the necessity for written informed consent was waived due to its retrospective design (Ethics committee approval was sent in the file named ethics). The study adhered to the principles of the Helsinki Declaration. Consent for publication: The materials described in the article, including all relevant raw data, are freely available to any scientist who wishes to use them for non-commercial purposes, without violating the privacy of participants. Added at the end of the main document. For manuscripts containing data of any individual in any form (including individual details, images or videos), permission to publish has been obtained from the individual in question or, in the case of children, from their parents or legal guardians. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: